Christoph Schrader PhD

Dr. Christoph Schräder leverages advanced proteomics and immunopeptidomics methods to characterize novel cancer-relevant pHLA targets for the development of innovative TCR-based immunotherapies. Immatics is a clinical-stage biotechnology company and the global leader in the precision targeting of PRAME. PRAME is a target expressed in more than 50 cancers, and Immatics has the broadest PRAME franchise with the most PRAME indications and modalities. Before joining Immatics, Dr. Christoph Schräder completed a Postdoctoral Fellowship at the University of Calgary (Canada) and earned his PhD from Martin Luther University Halle (Germany), where he applied structural mass spectrometry to uncover the cross-linking pattern of elastin.